comparemela.com

Page 6 - Sosei Heptares News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia

Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaSosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK,

Boehringer, Sosei Ink Potential $732M Deal for Schizophrenia Treatment

Boehringer Ingelheim has paid $27.3 million upfront to Sosei Heptares to develop a small molecule agonist of GPR52 to treat the positive, negative and cognitive symptoms of schizophrenia.

Boehringer, Sosei Heptares team up in schizophrenia drug deal

Boehringer Ingelheim Places €25M Bet on Sosei s Novel Approach to Schizophrenia

Boehringer Ingelheim Places €25M Bet on Sosei s Novel Approach to Schizophrenia
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.